Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MIF | P14174 | 2/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2467274 | 1.00 | TRPA1 (0.35) | TRPA1TSHRLMNAHPGDCYP2D6 | |
| SCHEMBL2436694 | 0.92 | TRPA1 (0.38) | TRPA1TSHRCYP2D6OPRL1OPRM1 | |
| SCHEMBL3360485 | 0.92 | TRPA1 (0.38) | TRPA1TSHRCYP2D6OPRL1OPRM1 | |
| SCHEMBL15011397 | 0.82 | CTSL (0.36) | LMNACTSL | |
| SCHEMBL625124 | 0.82 | ADRB2 (0.38) | TSHRLMNAHPGDOPRM1OPRK1 | |
| SCHEMBL624807 | 0.80 | SLC6A2 (0.40) | TSHRHPGDOPRL1OPRM1OPRD1 | |
| SCHEMBL15011535 | 0.80 | CTSL (0.36) | TSHROPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL624834 | 0.78 | PDE2A (0.37) | OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL31118220 | 0.78 | TSHR (0.44) | TRPA1TSHRLMNAOPRL1OPRM1 | |
| SCHEMBL625774 | 0.77 | ESR1 (0.36) | TSHRLMNAOPRL1OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137178-A1 | PERFUME SYSTEMS | THE PROCTER & GAMBLE COMPANY | 2010-06-03 | — | — | US | claimed |
| US-20260007672-A1 | INHIBITORS OF MPTP | NRG THERAPEUTICS LTD (GB) | 2026-01-08 | — | — | US | disclosed |
| US-12491185-B2 | Inhibitors of mPTP | NRG THERAPEUTICS LTD (GB) | 2025-12-09 | — | — | US | disclosed |
| EP-4652162-A1 | INHIBITORS OF MPTP | NRG Therapeutics LTD (GB) | 2025-11-26 | — | — | EP | disclosed |
| US-20250177397-A1 | INHIBITORS OF MPTP | NRG THERAPEUTICS LTD (GB) | 2025-06-05 | — | — | US | disclosed |
| WO-2024153946-A1 | INHIBITORS OF MPTP | NRG THERAPEUTICS LTD (GB) | 2024-07-25 | — | — | WO | disclosed |
| EP-2362765-B1 | PERFUME SYSTEMS | PROCTER & GAMBLE (US) | 2020-04-08 | — | — | EP | disclosed |
| US-9156788-B2 | TRPV3 modulators | ABBVIE INC. (US) | 2015-10-13 | — | — | US | disclosed |
| US-20130150409-A1 | NOVEL TRPV3 MODULATORS | ABBVIE INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-8431520-B2 | Perfume systems | THE PROCTER & GAMBLE COMPANY (US) | 2013-04-30 | — | — | US | disclosed |
| US-8431520-B2 | Perfume systems | THE PROCTER & GAMBLE COMPANY (US) | 2013-04-30 | — | — | US | disclosed |
| US-20130012422-A1 | PERFUME SYSTEMS | SMETS JOHAN (BE) | 2013-01-10 | — | — | US | disclosed |
| US-20130012422-A1 | PERFUME SYSTEMS | SMETS JOHAN (BE) | 2013-01-10 | — | — | US | disclosed |
| US-20100137178-A1 | PERFUME SYSTEMS | THE PROCTER & GAMBLE COMPANY | 2010-06-03 | — | — | US | disclosed |
| US-20100137178-A1 | PERFUME SYSTEMS | THE PROCTER & GAMBLE COMPANY | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12491185-B2 | Inhibitors of mPTP | PARK7, PINK1, SNCA | TRPA1 698/4885TSHR 3821/4885LMNA 4358/4885 |
| US-20130150409-A1 | NOVEL TRPV3 MODULATORS | TRPV3, TRPV4, TRPV5 | TRPA1 7/4885TSHR 1091/4885LMNA 2468/4885 |
| US-20130012422-A1 | PERFUME SYSTEMS | TRPA1, PORCN, PLIN5 | TRPA1 1/4885TSHR 4772/4885LMNA 2578/4885 |
| US-20100137178-A1 | PERFUME SYSTEMS | TRPA1, PORCN, PLIN5 | TRPA1 1/4885TSHR 4772/4885LMNA 2578/4885 |
| US-20250177397-A1 | INHIBITORS OF MPTP | PARK7, PINK1, SNCA | TRPA1 698/4885TSHR 3821/4885LMNA 4358/4885 |
| US-20260007672-A1 | INHIBITORS OF MPTP | PARK7, SNCA, CYC1 | TRPA1 244/4885TSHR 3311/4885LMNA 2300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.